InvestorsHub Logo
Followers 8
Posts 2018
Boards Moderated 0
Alias Born 07/19/2006

Re: Oren1976 post# 743

Monday, 03/27/2017 12:48:49 PM

Monday, March 27, 2017 12:48:49 PM

Post# of 2099
Oren, I heard the call and disagree. I believe he addressed the imbalance of drop outs here. Also, when referring to the ovarian cancer trials, I believe he was referring to the treatment landscape of PARP inhibitors and how that will change the treatment landscape. In rGBM, he discussed the interim analysis being close to studies' end.

Again, you may be right, but my listen to the conference call doesn't support how the control is doing. He mentioned that when patient's go off study they use checkpoints, and we know that's true as well before patient's going on study, they are using checkpoints.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News